Does achieving an intensive versus usual blood pressure level prevent stroke?

Annals of Neurology

Volumn 71, Issue 1, 2012, Pages 133-140

  Lee, Meng ^a   Saver, Jeffrey L ^b   Hong, Keun Sik ^c   Hao, Qing ^b   Ovbiagele, Bruce ^d  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Inje University   (South Korea)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; HUMAN; HYPOTENSION; META ANALYSIS; MORBIDITY; MORTALITY; ORGAN PERFUSION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; RISK REDUCTION; STROKE; SYSTOLIC BLOOD PRESSURE;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; HUMANS; HYPERTENSION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STROKE;

EID: 84856211571     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.22496     Document Type: Article

References (26)

1. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903-1913. (Pubitemid 35472129)
2. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560-2572. (Pubitemid 37430158)
3. Cushman WC, Evans GW, Byington RP, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010; 362: 1575-1585.
4. Peto R,. Why do we need systematic overviews of randomized trials? Stat Med 1987; 6: 233-244.
5. Moher D, Liberati A, Tetzlaff J, Altman DG,. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009; 339: b2535.
6. Law MR, Morris JK, Wald NJ,. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009; 338: b1665.
7. Arguedas JA, Perez MI, Wright JM,. Treatment blood pressure targets for hypertension. Cochrane Database Syst Rev 2009; 3: CD004349.
8. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1-12. (Pubitemid 26120810)
9. Higgins JP, Thompson SG,. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 1539-1558. (Pubitemid 34746062)
10. Higgins JP, Thompson SG, Deeks JJ, Altman DG,. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-560. (Pubitemid 37088507)
11. Higgins JPT, Green S,. Cochrane Handbook for Systematic Reviews of Interventions. West Sussex, The Cochrane Collaboration, 2008.
12. Mantel N, Haenszel W,. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22: 719-748.
13. Sterne JA, Egger M,. Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. J Clin Epidemiol 2001; 54: 1046-1055. (Pubitemid 32888370)
14. Nissen SE, Tuzcu EM, Libby P, et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 2004; 292: 2217-2225.
15. McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003; 362: 767-771. (Pubitemid 37093916)
16. Flather MD, Yusuf S, Kober L, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 2000; 355: 1575-1581. (Pubitemid 30240501)
17. Schrier RW, Estacio RO, Esler A, Mehler P,. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 2002; 61: 1086-1097. (Pubitemid 34175478)
18. Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003; 362: 772-776. (Pubitemid 37093917)
19. Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003; 362: 777-781. (Pubitemid 37093918)
20. Bosch J, Yusuf S, Gerstein HC, et al. Effect of ramipril on the incidence of diabetes. N Engl J Med 2006; 355: 1551-1562. (Pubitemid 44550032)
21. Fox KM,. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782-788. (Pubitemid 37093919)
22. Cooper-DeHoff RM, Gong Y, Handberg EM, et al. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA 2010; 304: 61-68.
23. MacMahon S, Sharpe N, Gamble G, et al. Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease. PART-2 Collaborative Research Group. Prevention of Atherosclerosis with Ramipril. J Am Coll Cardiol 2000; 36: 438-443. (Pubitemid 30624005)
24. Braunwald E, Domanski MJ, Fowler SE, et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004; 351: 2058-2068.
25. Asselbergs FW, Diercks GF, Hillege HL, et al. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation 2004; 110: 2809-2816. (Pubitemid 39473602)
26. Pitt B, Byington RP, Furberg CD, et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation 2000; 102: 1503-1510.